Table 1

Patient characteristics

CharacteristicNo.%
No. of patients 79  
Age, y   
 Median 64 
 Range 40-86 
Gender   
 Male 37  
 Female 42  
ISS stage   
 I 27 34.2 
 II 31 39.2 
 III 21 26.6 
ECOG performance status   
 0-1 75  
 ≥2 4  
β2 microglobulin, mg/L   
 Median 3.8 
 Range 1.2-36.7 
IgG 36 45.6 
IgA 16 32.9 
Light chain myeloma 18 22.8 
Oligosecretory myeloma 9 11.4 
FISH-defined cytogenetic risk groups   
 High risk: t(4;14), t(14;16), del17p, 1q21 30 43.5* 
 Standard risk: all others 39 56.5* 
Prior treatment lines   
 Median 2 
 Range 1-6 
Prior exposure to bortezomib 50 63.3 
Prior exposure to lenalidomide 42 53.2 
Prior exposure to both bortezomib and lenalidomide 29 36.7 
CharacteristicNo.%
No. of patients 79  
Age, y   
 Median 64 
 Range 40-86 
Gender   
 Male 37  
 Female 42  
ISS stage   
 I 27 34.2 
 II 31 39.2 
 III 21 26.6 
ECOG performance status   
 0-1 75  
 ≥2 4  
β2 microglobulin, mg/L   
 Median 3.8 
 Range 1.2-36.7 
IgG 36 45.6 
IgA 16 32.9 
Light chain myeloma 18 22.8 
Oligosecretory myeloma 9 11.4 
FISH-defined cytogenetic risk groups   
 High risk: t(4;14), t(14;16), del17p, 1q21 30 43.5* 
 Standard risk: all others 39 56.5* 
Prior treatment lines   
 Median 2 
 Range 1-6 
Prior exposure to bortezomib 50 63.3 
Prior exposure to lenalidomide 42 53.2 
Prior exposure to both bortezomib and lenalidomide 29 36.7 

ECOG, Eastern Cooperative Oncology Group; IgG, immunoglobulin G.

*

Cytogenetic results available from 60 patients: t (4;14), 10; t(14;16), 1; del17p, 9; 1q21, 22 (20 patients had ≥2 aberrations).

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal